G. Masi

Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study

Background Regorafenib is a treatment option for refractory metastatic colorectal cancer (mCRC) patients. The identification of markers to predict or monitor the efficacy of regorafenib r...

F. Marmorino ;

Filippo Pietrantonio ;

A. Boccaccino ;

C. Cremolini ;

M. Antista ;

N. Zaffaroni ;

G. Zucchelli ;

A. Martinetti ;

E. Campi ;

E. Sottotetti ;

B. Borelli ;

F. Corti ;

V. Conca ;

R. Moretto ;

M. Germani ;

A. Falcone ;

M. Giordano ;

C. Antoniotti ;

G. Masi ;

07/02/2021

Extended molecular profiling in patients with biliary tract cancers: Impact of the BRCAness phenotype in patients management

BackgroundAlthough the pathogenetic role of BRCAness phenotype in other malignancies, such as breast and ovarian cancer, has been widely investigated, its role in biliary tract cancer (BT...

Dario Berra ;

Jessica Graziani ;

Linda Bartalini ;

Giada Grelli ;

Valentina Caputo ;

Enrico Vasile ;

Lorenzo Fornaro ;

Virginia Genovesi ;

Benedetta Toschi ;

Caterina Vivaldi ;

Caterina Congregati ;

Miriam Caccese ;